Key takeaways
View moreAmgen appears moderately undervalued based on its strong financial performance, robust pipeline, and current valuation multiples below industry averages. The company's ability to generate strong cash flows and maintain above-average profitability metrics, coupled with significant growth opportunities from its R&D pipeline and geographic expansion, suggest potential for value appreciation. However, risks such as pricing pressures and high debt levels partially offset this upside potential.
- Amgen has demonstrated strong revenue growth, driven by successful product launches and the acquisition of Horizon Therapeutics.
- The company's financial performance is characterized by strong profitability, robust cash flow generation, and efficient asset utilization.
- Amgen faces significant pricing and reimbursement pressures, particularly from government actions like the Inflation Reduction Act, which could impact future revenue growth and profitability.
- The company's robust pipeline, particularly in areas like obesity and oncology, positions it for continued growth and market leadership.
- Amgen's global footprint and strategic partnerships provide significant opportunities for expansion and revenue growth in international markets.
- The company's valuation is currently below the industry average, suggesting potential upside.
- Amgen's future outlook is positive, with continued growth expected across multiple product lines. However, investors should carefully consider the risks associated with the company's business, such as pricing and reimbursement pressures, competition, and regulatory risks.
Evaluation summary
-
Company Overview:
- Amgen is a global biotechnology company that discovers, develops, manufactures, and markets human therapeutics. The company operates in one business segment: human therapeutics.
- Amgen's key products include Prolia, ENBREL, XGEVA, Repatha, Otezla, TEPEZZA, KYPROLIS, EVENITY, Aranesp, Nplate, KRYSTEXXA, Vectibix, BLINCYTO, and TEZSPIRE.
- The company's revenue is generated from the sale of these products, with significant contributions from the recent acquisition of Horizon Therapeutics, which expanded Amgen's rare disease portfolio with products like TEPEZZA, KRYSTEXXA, and UPLIZNA.
- For comparative analysis, Amgen is benchmarked against the Health Care Select Sector SPDR Fund (XLV) and compared to industry peers Regeneron Pharmaceuticals, Inc. (REGN) and Vertex Pharmaceuticals, Inc. (VRTX).
-
Financial Performance:
- Amgen has demonstrated strong revenue growth in recent quarters, with total revenue reaching $33.4 billion in 2024, a 19% year-over-year increase. This growth was driven by strong product sales growth (19%, fueled by 23% volume growth).
- The company's gross profit margin has been improving, indicating effective cost management. However, the Horizon acquisition has impacted gross margins due to higher amortization of acquisition-related assets.
- Amgen's profitability is strong, with a net profit margin significantly above the industry average. The company's return on assets, return on equity, and return on capital are all significantly above the industry average, indicating efficient asset utilization.
- The company's non-GAAP operating margin was 47% in 2024, and non-GAAP EPS was accretive due to the Horizon acquisition.
- Recent news highlights the impact of the Inflation Reduction Act on pricing and reimbursement, which could potentially impact future revenue growth.
-
Operational Efficiency:
- Amgen's balance sheet shows a strong short-term liquidity position, with a current ratio above the industry average. However, the company's quick ratio is below the industry average, suggesting potential challenges in meeting short-term obligations without relying on inventory sales.
- The company's working capital has been decreasing in recent quarters, suggesting potential challenges in managing short-term obligations.
- Amgen has strong cash flow generation, with robust operating cash flow and free cash flow. The company's operating cash flow growth has been consistently higher than its net income growth, suggesting a high quality of earnings.
- Amgen's free cash flow margin has been increasing in recent quarters, indicating strong cash flow generation. The company's strong operating cash flow provides it with the flexibility to repay debt, increase dividends, and invest in future growth opportunities.
- Amgen's capital expenditures have been relatively stable in recent quarters, while depreciation has been increasing.
- The company has a history of returning capital to shareholders through dividends and share repurchases.
- Amgen's liquidity ratios are generally strong, with a current ratio and quick ratio above the industry average.
- The company's debt-to-equity ratio and leverage ratios are significantly above the industry average, indicating a high level of financial leverage.
-
Growth Opportunities:
- Amgen is focused on expanding its market presence through new product launches, expansion into new indications for existing products, and strategic acquisitions.
- The company has a robust R&D pipeline, with several key Phase III data readouts expected in 2025 across various therapeutic areas. Amgen is investing heavily in R&D, reflecting its commitment to innovation and future growth.
- Amgen is pursuing geographic expansion, particularly in international markets. The company's global footprint and strategic partnerships, such as the one with BeiGene in China, provide significant opportunities for expansion and revenue growth.
- Amgen's strategic focus areas include advancing its pipeline in areas like obesity and oncology, expanding access to key products like Repatha and EVENITY, launching TEPEZZA internationally, and advancing its biosimilars pipeline.
- The company is making progress on previously announced initiatives, such as the integration of Horizon Therapeutics, which is progressing well, with cost synergies expected to reach $500 million within three years.
- Amgen's capital allocation strategies are aligned with its growth objectives, with a focus on investing in R&D, expanding its product portfolio, and returning capital to shareholders.
-
Recent Developments and Market Sentiment:
- Recent news highlights the impact of the Inflation Reduction Act on pricing and reimbursement, which could potentially impact future revenue growth.
- The company's strong financial performance and robust pipeline have been well-received by investors, with a positive market sentiment.
- Analysts are particularly interested in the performance of key products like Repatha and the potential of the pipeline, particularly in areas like obesity and oncology.
-
Risks and Threats:
- Amgen faces significant pricing and reimbursement pressures, particularly from government actions like the Inflation Reduction Act, which will likely have a material adverse impact on sales and profitability.
- The company's high debt levels could limit its financial flexibility in the future, particularly if interest rates rise or economic conditions deteriorate.
- Amgen's manufacturing capabilities, supply chain, and IT infrastructure are critical to its operations, but also expose it to risks like supply disruptions, cybersecurity breaches, and regulatory issues.
- The company faces competition from other biotechnology companies, as well as from biosimilar manufacturers.
- Amgen is subject to regulatory oversight, which could lead to delays in product approvals or restrictions on product use.
- The company is involved in ongoing patent litigation related to some of its key products.
-
Valuation Analysis:
- Amgen's valuation metrics, such as EV/EBITDA and EV/Sales, are significantly below the industry average, indicating a lower valuation relative to its revenue and earnings.
- Potential catalysts for Amgen's stock price include successful product launches, expansion into new indications for existing products, and positive clinical trial results.
-
Price Performance:
- Amgen's stock price has generally outperformed the Health Care Select Sector SPDR Fund (XLV) over the past three years, particularly in the longer timeframes. However, AMGN has underperformed VRTX in most periods, especially in the longer timeframes.
- Recent price movements have been influenced by news events, such as the company's strong financial performance and the impact of the Inflation Reduction Act.
-
Future Outlook:
- Amgen's management has provided guidance for 2025, expecting total revenues of $34.3 billion to $35.7 billion and non-GAAP EPS between $20 and $21.20.
- Analysts are generally optimistic about Amgen's future prospects, with consensus price targets suggesting potential upside.
- Recent news and developments, such as the impact of the Inflation Reduction Act and the company's robust pipeline, are expected to influence Amgen's future performance.
-
Summary:
- Amgen is a well-established biotechnology company with a strong financial position and a robust pipeline. The company has demonstrated strong revenue growth, driven by successful product launches and the acquisition of Horizon Therapeutics.
- Amgen's financial performance is characterized by strong profitability, robust cash flow generation, and efficient asset utilization. However, the company faces significant challenges related to pricing and reimbursement pressures, competition, and regulatory risks.
- The company's valuation is currently below the industry average, suggesting potential upside.
- Amgen's future outlook is positive, with continued growth expected across multiple product lines. However, investors should carefully consider the risks associated with the company's business, such as pricing and reimbursement pressures, competition, and regulatory risks.
- Key areas to monitor in the future include the impact of the Inflation Reduction Act on pricing and reimbursement, the company's progress in advancing its pipeline, and the company's ability to manage its debt levels.
Price history
Fundamentals
Insights
- Amgen has demonstrated strong revenue growth, driven by the successful launch of new products and the acquisition of Horizon Therapeutics.
- The company has a strong profitability profile, with improving gross margins and increasing operating margins.
- Amgen has a strong short-term liquidity position, as evidenced by its current ratio, which is above the industry average.
- The company has a high level of financial leverage, as evidenced by its debt-to-equity ratio and debt-to-EBITDA ratio, which are both significantly above the industry average.
- Amgen is highly efficient in utilizing its assets to generate revenue, as evidenced by its strong return on assets, return on equity, and return on capital.
- The company has strong cash flow generation, with robust operating cash flow and free cash flow.
- Amgen faces significant pricing and reimbursement pressures, particularly from government actions like the Inflation Reduction Act, which will likely have a material adverse impact on sales and profitability.
- The company's high debt levels could limit its financial flexibility in the future, particularly if interest rates rise or economic conditions deteriorate.
- The company's manufacturing capabilities, supply chain, and IT infrastructure are critical to its operations, but also expose it to risks like supply disruptions, cybersecurity breaches, and regulatory issues.
- Amgen's diversified product portfolio, strategic acquisitions, and financial strength position it well for the future, despite the significant risks it faces.
Analysis
-
Revenue - Amgen has demonstrated strong revenue growth, driven by the successful launch of new products and the acquisition of Horizon Therapeutics. - The company's revenue growth has been driven by a combination of organic growth and acquisitions. - The company's revenue growth is expected to continue, driven by new product launches and expansion into new indications for existing products. - The company has acknowledged the impact of the Inflation Reduction Act on pricing and reimbursement, which could potentially impact future revenue growth.
-
Profitability
- Amgen has a strong profitability profile, with improving gross margins and increasing operating margins.
- The company's return on assets, return on equity, and return on capital are all significantly above the industry average, indicating efficient asset utilization.
- The company's net profit margin is significantly above the industry average, indicating strong overall profitability.
- The Horizon acquisition has had a mixed impact on the company's financial performance, with increased revenue but also higher amortization expenses.
-
Liquidity
- Amgen has a strong short-term liquidity position, as evidenced by its current ratio, which is above the industry average.
- The company's quick ratio is below the industry average, suggesting potential challenges in meeting short-term obligations without relying on inventory sales.
- The decreasing trend in working capital suggests potential challenges in managing short-term obligations.
-
Solvency
- Amgen has a high level of financial leverage, as evidenced by its debt-to-equity ratio and debt-to-EBITDA ratio, which are both significantly above the industry average.
- This could raise concerns about long-term solvency, especially if interest rates rise.
- The company's ability to generate free cash flow, despite its high debt levels, suggests a strong long-term solvency position.
-
Operational Efficiency
- Amgen is highly efficient in utilizing its assets to generate revenue, as evidenced by its strong return on assets, return on equity, and return on capital.
- The company's gross profit margin is significantly above the industry average, indicating effective cost management.
- The company's enterprise value to sales and enterprise value to EBITDA ratios are significantly below the industry average, indicating a lower valuation relative to its revenue and earnings.
-
Cash Flow Analysis
- Amgen has strong cash flow generation, with robust operating cash flow and free cash flow.
- The company's operating cash flow growth has been consistently higher than its net income growth, suggesting a high quality of earnings.
- The company's strong operating cash flow provides it with the flexibility to repay debt, increase dividends, and invest in future growth opportunities.
- The company's acquisition strategy has been active, with the recent acquisition of Horizon Therapeutics being a significant example.
-
Risk Factors
- Amgen faces significant pricing and reimbursement pressures, particularly from government actions like the Inflation Reduction Act, which will likely have a material adverse impact on sales and profitability.
- The company's high debt levels could limit its financial flexibility in the future, particularly if interest rates rise or economic conditions deteriorate.
- The company's manufacturing capabilities, supply chain, and IT infrastructure are critical to its operations, but also expose it to risks like supply disruptions, cybersecurity breaches, and regulatory issues.
- The company's financial performance remains strong, with robust revenue growth, though margins are being pressured by acquisition-related costs and amortization.
-
Future Outlook
- Amgen's diversified product portfolio, strategic acquisitions, and financial strength position it well for the future, despite the significant risks it faces.
- The company's revenue growth is expected to continue, driven by new product launches and expansion into new indications for existing products.
- The company's profitability is expected to remain strong, with continued improvement in gross margins and operating margins.
- The company's net income is expected to be impacted by the Horizon acquisition and increased amortization expenses in the near term.
- Key metrics to monitor in upcoming quarters include operating cash flow growth, free cash flow generation, capital expenditures, debt levels, and asset utilization efficiency.
-
Financial statements
Public filings
- Amgen has transformed into a leading global biotechnology company through strategic acquisitions like Horizon Therapeutics, expanding its rare disease portfolio and pipeline.
- The company faces significant pricing and reimbursement pressures, particularly from government actions like the Inflation Reduction Act, which will likely have a material adverse impact on sales and profitability.
- Amgen's manufacturing capabilities, supply chain, and IT infrastructure are critical to its operations, but also expose it to risks like supply disruptions, cybersecurity breaches, and regulatory issues.
- The company's financial performance remains strong, with robust revenue growth, though margins are being pressured by acquisition-related costs and amortization.
- Amgen continues to invest heavily in R&D to advance its pipeline, but also faces legal and tax risks that could result in substantial liabilities.
- Overall, Amgen appears to be navigating a challenging operating environment, but its diversified product portfolio, strategic acquisitions, and financial strength position it well for the future, despite the significant risks it faces.
-
Core Business and Operations:
- Amgen is a global biotechnology pioneer that discovers, develops, manufactures and delivers innovative human therapeutics
- Key products include Prolia, ENBREL, XGEVA, Repatha, Otezla, TEPEZZA, KYPROLIS, EVENITY, Aranesp, Nplate, KRYSTEXXA, Vectibix, BLINCYTO and TEZSPIRE
- Operates in one business segment: human therapeutics
- Acquired Horizon Therapeutics in October 2023, expanding rare disease portfolio with products like TEPEZZA, KRYSTEXXA and UPLIZNA
-
Industry and Market Trends:
- Facing uncertain macroeconomic conditions, including higher inflation, rising interest rates, and instability in the financial system
- Industry subject to significant pricing pressures and cost containment measures from governments and private payers
- Provisions of the Inflation Reduction Act (IRA) have affected and will continue to impact pricing and reimbursement, particularly for Medicare-covered drugs
- Ongoing geopolitical conflicts create additional uncertainty in global macroeconomic conditions
-
Recent Events:
- Completed acquisition of Horizon Therapeutics in October 2023 for $27.8 billion
- Received FDA approvals for IMDELLTRA in small cell lung cancer and BLINCYTO in frontline acute lymphoblastic leukemia
- Announced positive topline results for UPLIZNA in IgG4-related disease and rocatinlimab in atopic dermatitis
-
Risk Factors:
- Pricing and reimbursement pressures from government and commercial payers, including impact of IRA legislation
- Potential for further pricing and access restrictions at the state level, including through drug affordability review boards
- Consolidation of private payers and PBMs leading to increased negotiating leverage and discounts
- Cybersecurity risks and potential for data breaches or IT system disruptions
- Ongoing tax disputes with the IRS and potential for additional tax liabilities
- Manufacturing difficulties or supply chain disruptions impacting ability to produce and distribute products
-
Legal Matters:
- Ongoing patent litigation related to Repatha, Prolia and XGEVA
- Antitrust lawsuits related to Sensipar and ENBREL
- Tax disputes with the IRS over allocation of profits between U.S. and Puerto Rico entities
-
Management's Discussion and Analysis:
- Total product sales increased 22-24% driven by volume growth of 26-27%, partially offset by net selling price declines of 2-3%
- Significant contribution from acquired Horizon products, including TEPEZZA and KRYSTEXXA
- Gross margins impacted by higher amortization of Horizon acquisition-related assets
- R&D and SG&A expenses increased due to Horizon integration and pipeline advancement
- Effective tax rates declined due to Horizon acquisition and mix of earnings
- Strong cash flow generation, with plans to continue investing in business, reducing debt, and returning capital to shareholders
Earnings calls
Earnings Report 2024Q4 (2025-02-04)
Key takeaways
-
Strong Underlying Growth: Despite headwinds from biosimilars and price erosion, Amgen demonstrated strong underlying growth in its core business, driven by successful product launches and expansion into new indications.
-
Robust Pipeline a Key Differentiator: Amgen's diverse and robust pipeline, particularly in areas like obesity and oncology, positions the company for continued growth and market leadership. The significant R&D investment underscores this commitment.
-
Strategic Acquisitions Enhance Portfolio: The Horizon acquisition has proven accretive to earnings and expanded Amgen's presence in attractive therapeutic areas, further strengthening its overall portfolio.
-
Biosimilars Remain a Growth Engine: Amgen's biosimilars business continues to be a significant revenue driver, with successful launches and a strong pipeline suggesting continued growth in this segment.
-
Global Expansion Offers Significant Opportunities: Amgen's global footprint and strategic partnerships, such as the one with BeiGene in China, provide significant opportunities for expansion and revenue growth in international markets.
-
Management Confidence High Despite Challenges: Despite acknowledging competitive pressures and industry headwinds, management expressed strong confidence in Amgen's ability to deliver on its long-term growth objectives.
-
Investor Focus on Key Products and Pipeline: Analyst questions highlighted a strong focus on the performance of key products like Repatha and the potential of the pipeline, particularly in areas like obesity and oncology. This underscores the importance of these areas for future growth.
Focus of management’s prepared remarks
-
Strong 2024 Performance and Future Outlook: Amgen highlighted its strong operational execution in 2024, leading to revenue growth and EPS growth despite challenges. Management expressed confidence in maintaining this momentum in 2025 and beyond, emphasizing the company's ability to navigate industry headwinds.
-
Key Growth Drivers: The company specifically identified Repatha, EVENITY, and TEZSPIRE as key near-term growth drivers, emphasizing their significant market potential and strong performance in 2024. The innovative oncology portfolio and biosimilars were also highlighted as significant contributors to revenue growth.
-
Robust Pipeline and R&D Investment: Amgen emphasized the strength of its pipeline, with several key Phase III data readouts expected in 2025 across various therapeutic areas. Significant R&D investment was highlighted, reflecting the company's commitment to innovation and future growth. The MariTide program in obesity was specifically mentioned as a promising area of development.
-
Global Expansion and Biosimilars: Management discussed the company's global expansion strategy, highlighting the growth opportunities in international markets. The biosimilars portfolio was also emphasized as a key growth driver, with several upcoming launches planned for 2025.
-
Operational Excellence and Efficiency: Amgen highlighted its operational excellence and efficiency initiatives, emphasizing the company's ability to manage costs and deliver strong margins despite increased R&D investment. The successful integration of Horizon Therapeutics was also mentioned.
Focus of the analyst Q&A
-
Repatha's Future Growth and Competition: Analysts inquired about the long-term growth prospects for Repatha, considering the emergence of oral PCSK9 inhibitors and upcoming clinical trial data from competitors. Concerns were raised regarding the potential impact of these competitive threats on Repatha's market share and pricing.
-
AMGEVITA's Sustainability and Biosimilar Performance: Analysts sought clarification on the sustainability of AMGEVITA's strong performance and the overall outlook for Amgen's biosimilar portfolio. Questions were raised about the drivers of AMGEVITA's success and the company's expectations for future biosimilar launches.
-
2025 Sales Guidance and Part D Redesign: Analysts sought further detail on the company's 2025 sales guidance, specifically asking where the Street might be underestimating growth and how the Part D redesign was factored into the projections.
-
Horizon Products' Growth and Competition: Analysts inquired about the growth potential of specific Horizon products, such as KRYSTEXXA, and the competitive landscape for TEPEZZA. Questions were raised about the potential for biosimilar competition and the company's strategies to maintain market share.
-
Obesity Portfolio Strategy: Analysts questioned Amgen's strategic approach to the obesity market, given previous setbacks with some obesity assets and the intense competition in this area. The company's appetite for further expansion in this market and potential additions to its portfolio were also questioned.
-
Repatha VESALIUS Study and Portfolio Synergies: Analysts sought insights into the expected learnings from the Repatha VESALIUS study and how these learnings could be leveraged across other programs, such as olpasiran and MariTide. Questions were raised about potential synergies between these programs.
-
M&A Strategy Post-Horizon Acquisition: Analysts inquired about Amgen's stance on pursuing overseas clinical-stage assets and its overall appetite for M&A activity following the Horizon acquisition.
-
MariTide Phase III Program and Dosing: Analysts sought clarification on the specific indications for the upcoming MariTide Phase III trials and whether these trials would include head-to-head comparisons against competitors. Questions were also raised about the potential for interim looks at data from ongoing Phase II studies to inform the design of the Phase III program.
-
TEPEZZA's International Growth: Analysts asked about the growth prospects for TEPEZZA in both the U.S. and international markets, specifically focusing on the Japan launch and the potential for a rapid ramp-up in sales similar to the U.S. launch.
-
China Market Opportunity: Analysts inquired about Amgen's commercial opportunities in China, particularly for its oncology medicines, and the role of its partnership with BeiGene in achieving these goals.
-
Denosumab Biosimilar Erosion: Analysts sought clarification on the expected cadence of biosimilar erosion for denosumab, particularly regarding the timing of biosimilar entry and the potential impact on sales.
-
Rocatinlimab ROCKET Program: Analysts asked about the key data points to watch for in the upcoming readouts from the Rocatinlimab ROCKET program and how these data would inform the company's competitive positioning in the atopic dermatitis market.
Summary
-
Financial Performance: Amgen reported strong financial performance for Q4 and FY2024. Total revenues reached $33.4 billion, a 19% year-over-year increase, driven by strong product sales growth (19%, fueled by 23% volume growth). Product sales excluding Horizon acquisitions still showed a 7% increase, demonstrating underlying business strength. Non-GAAP operating margin was 47%, and non-GAAP EPS was accretive due to the Horizon acquisition. Free cash flow was robust at $10.4 billion for the full year. Specific comparisons to prior analyst expectations were not explicitly stated.
-
Revenue Drivers: Key revenue drivers included strong performance from Repatha (36% sales increase, reaching over $2.2 billion), EVENITY (35% sales increase, reaching almost $1.6 billion), and TEZSPIRE (71% increase, reaching nearly $1 billion). The innovative oncology portfolio also contributed significantly, with an 11% year-over-year sales increase. Biosimilars contributed $2.2 billion in sales, a 16% year-over-year increase. The launch of PAVBLU (a biosimilar to EYLEA) generated $31 million in sales in its first 9 weeks. The company highlighted the significant unmet needs and large addressable markets for many of these products, suggesting substantial future growth potential.
-
Profit Margins and Cost Management: Amgen maintained a strong non-GAAP operating margin of 47% for FY2024. Increased R&D spending (25% year-over-year increase to $5.9 billion) reflected investments in the late-stage pipeline. The company expects a non-GAAP operating margin of roughly 46% for 2025, with non-GAAP R&D expense projected to grow in the mid-teens. Non-GAAP SG&A spend is expected to decline by 1-2 percentage points as a percentage of product sales due to efficiency initiatives. The Horizon acquisition contributed to increased interest expense, impacting other income and expense.
-
Guidance and Outlook: Amgen provided 2025 guidance of $34.3 billion to $35.7 billion in total revenues and non-GAAP EPS between $20 and $21.20. This reflects expectations of continued growth across multiple product lines, offsetting declines from patent expirations and price erosion. The company acknowledged potential variability in biosimilar sales due to customer ordering patterns. Risks include continued price pressure, biosimilar competition, and the impact of the Part D redesign. Opportunities include the launch of new products and expansion into new indications for existing products.
-
Strategic Initiatives: Key strategic initiatives include advancing the MariTide program in obesity, initiating Phase III studies for TEZSPIRE in COPD, and continuing development of the bispecific T-cell engager platform. The company is also focused on expanding access to Repatha and EVENITY, launching TEPEZZA internationally, and advancing its biosimilars pipeline. Amgen highlighted its commitment to innovation and leveraging AI across its value chain. The integration of Horizon Therapeutics is progressing well, with cost synergies expected to reach $500 million within three years.
-
Management Commentary: Management expressed confidence in Amgen's strong execution, diverse portfolio, and robust pipeline. They emphasized the company's ability to deliver long-term growth despite challenges such as biosimilar competition and price erosion. The overall tone was positive and optimistic, highlighting the numerous growth opportunities across therapeutic areas. Specific quotes emphasized the strong performance of key products, the potential of the pipeline, and the company's commitment to innovation and patient care.
-
Industry and Market Conditions: Amgen acknowledged the competitive landscape in various therapeutic areas, including the emergence of oral PCSK9 inhibitors and biosimilars. The company highlighted the significant unmet needs in areas such as cardiovascular disease, bone health, and rare diseases, suggesting substantial market opportunities. The Part D redesign was mentioned as having a relatively neutral impact on the overall portfolio. Management expressed confidence in Amgen's ability to navigate these market dynamics and maintain its leadership position.
Comparative analysis
Benchmarks (as of 2025-02-14)
- Performance Comparison: AMGN has generally outperformed XLV over the analyzed periods. AMGN has shown consistent outperformance in the longer-term periods, such as 2 years and 3 years. However, in the shorter-term periods, such as 6 months, AMGN has underperformed XLV.
- Risk and Return Analysis: AMGN has provided higher annualized returns than XLV over the analyzed periods. However, AMGN has also been more volatile than XLV, as indicated by its higher annualized volatility. AMGN's larger maximum drawdown compared to XLV suggests that it carries a higher risk profile.
- Risk-Adjusted Performance: XLV has generally offered a better risk-adjusted return than AMGN, as indicated by its higher Sharpe ratio. This suggests that XLV has been more efficient in generating returns relative to its risk. AMGN's lower beta suggests that it is less sensitive to market movements than XLV, making it a less risky investment.
- Overall Assessment: AMGN has shown strong historical performance, outperforming XLV in most periods. However, its higher volatility and larger maximum drawdown suggest that it carries a higher risk profile. While AMGN has provided higher returns, XLV has offered a better risk-adjusted return, as indicated by its higher Sharpe ratio. AMGN's lower beta suggests that it is less sensitive to market movements than XLV, making it a less risky investment. Investors should consider their risk tolerance and investment goals when evaluating AMGN and XLV.
Peers Price History(as of 2025-02-14)
- Performance Comparison: AMGN has generally outperformed REGN over the past three years, particularly in the longer timeframes. However, AMGN has underperformed VRTX in most periods, especially in the longer timeframes. This suggests that AMGN may be a more stable investment than REGN but may not be as growth-oriented as VRTX.
- Risk and Return Analysis: AMGN has provided higher annualized returns than REGN over the past three years, but lower returns than VRTX. AMGN's volatility has been lower than REGN's but higher than VRTX's. AMGN's maximum drawdown has been lower than REGN's but higher than VRTX's. This suggests that AMGN may be a more balanced investment than REGN, offering a lower risk profile but also lower potential returns.
- Risk-Adjusted Performance: VRTX has consistently shown a higher Sharpe ratio than AMGN and REGN, indicating that VRTX is offering the best risk-adjusted return. AMGN's lower beta suggests a lower risk profile compared to REGN and VRTX. This suggests that VRTX may be the most attractive investment from a risk-adjusted return perspective, while AMGN may be a more conservative option.
- Overall Assessment: AMGN appears to be a more stable and less volatile investment than REGN, but it may not be as growth-oriented as VRTX. AMGN's lower beta suggests a lower risk profile, but it also comes with lower potential returns. VRTX has consistently shown a higher Sharpe ratio, indicating better risk-adjusted returns. Investors seeking a more conservative investment with lower volatility may consider AMGN, while investors seeking higher growth potential and risk-adjusted returns may consider VRTX.
Peers Fundamentals(as of 2024-12-31)
-
Market Position and Size:
- AMGN is the largest company in the peer group, with a market capitalization of 156,508 million, significantly larger than REGN's 73,641.4 million and VRTX's 118,206 million. This size advantage is reflected in AMGN's revenue, which is more than double that of REGN and nearly triple that of VRTX. AMGN's EBITDA is also significantly higher than its peers, further highlighting its scale and market dominance.
-
Profitability and Efficiency:
- AMGN's profitability metrics are generally lower than its peers and industry averages. While AMGN's Gross Profit Margin of 78.7% is relatively high, it is lower than REGN's 82.73% and VRTX's 86.07%. AMGN's EBITDA Margin is not available, but REGN's 32.37% is significantly higher than the industry average of -19,446.19%. AMGN's Net Profit Margin of 12.29% is significantly lower than REGN's 31.07% and VRTX's -4.88%. This suggests that AMGN may face higher operating costs or have less efficient revenue generation compared to its peers.
- AMGN's return on capital metrics are mixed compared to its peers and industry averages. AMGN's Return on Average Assets of 4.33% is lower than REGN's 12.43% but higher than VRTX's -2.32%. Similarly, AMGN's Return on Average Total Equity of 67.55% is significantly higher than REGN's 15.95% and VRTX's -3.15%. However, AMGN's Return on Average Total Capital of 12.74% is lower than REGN's 13.5% and VRTX's -0.99%. These mixed results suggest that AMGN may be more efficient in utilizing equity capital but less efficient in utilizing total capital compared to its peers.
-
Financial Health and Stability:
- AMGN's liquidity and solvency metrics are significantly different from its peers and industry averages. AMGN's Current Ratio of 1.26 is significantly lower than REGN's 4.73 and VRTX's 2.69, and well below the industry average of 7.87. Similarly, AMGN's Quick Ratio of 0.95 is lower than REGN's 3.95 and VRTX's 2.35, and significantly lower than the industry average of 7.77. This suggests that AMGN may have a lower level of short-term liquidity compared to its peers. However, AMGN's Total Debt to Total Equity Ratio of 1022.61 is significantly higher than REGN's 10.01 and VRTX's 10.66, and far exceeds the industry average of 111.05. This indicates that AMGN has a significantly higher level of debt compared to its peers and the industry.
-
Valuation and Market Perception:
- AMGN's valuation metrics are generally higher than its peers and industry averages. AMGN's Enterprise Value To Sales of 5.69 is higher than REGN's 5.28 but lower than VRTX's 9.15. AMGN's Price To Earnings of 38.51 is significantly higher than REGN's 17.57 and the industry average of 79.84. AMGN's Price to Book Ratio of 26.6 is significantly higher than REGN's 2.52 and VRTX's 7.19, and well above the industry average of 6.65. These higher valuation metrics suggest that the market may be placing a premium on AMGN's size, brand recognition, and potential for future growth.
-
Cash Flow and Capital Management:
- AMGN's cash flow metrics are generally higher than its peers, considering their market caps. AMGN's Net Operating Cash Flow of 11,490 million is significantly higher than REGN's 4,420.5 million and VRTX's -492.6 million. AMGN's Total Capital Expenditure is not available, but REGN's 881.6 million is significantly lower than VRTX's 485.4 million. AMGN's Free Cash Flow is not available, but REGN's 3,538.9 million is significantly higher than VRTX's -978 million. This suggests that AMGN is generating strong cash flow from operations and may have a more conservative approach to capital expenditures compared to its peers.
-
Growth and Future Prospects:
- AMGN's growth trends are mixed compared to its peers. AMGN's revenue growth has been consistently higher than the peer group average over the past 5 years, with a 5-year CAGR of 7.42% compared to the peer average of 13.86%. However, AMGN's net income growth has been consistently lower than the peer group average, with a 5-year CAGR of -12.21% compared to the peer average of 1.81%. This suggests that AMGN's revenue growth has not been translating into corresponding profit growth, potentially due to higher operating costs or other factors.
- AMGN's year-over-year growth rates have been relatively volatile, particularly for net income and basic earnings per share. This volatility is reflected in the high standard deviations for these metrics. For example, the standard deviation for AMGN's net income growth over the past 5 years is 59.12%, indicating significant fluctuations from year to year.
- AMGN's 3-year CAGR for sales/revenue is higher than its 5-year CAGR, suggesting an acceleration in revenue growth in recent years. However, this acceleration is not reflected in net income or basic earnings per share, where the 3-year CAGRs are lower than the 5-year CAGRs. This suggests that AMGN's recent revenue growth may not be sustainable in terms of profitability.
- Overall, AMGN's growth profile is characterized by strong revenue growth but weak profit growth. This suggests that AMGN may be facing challenges in translating its revenue growth into profitability.
-
Potential for Investment:
- AMGN's investment attractiveness is mixed. The company's size, revenue growth, and strong cash flow generation are positive factors. However, its lower profitability, efficiency, and high debt levels are potential concerns. Investors should carefully consider these factors before making an investment decision.
-
Key Risks and Considerations:
- Profitability and Efficiency: AMGN's lower profitability and efficiency compared to its peers raise concerns about its long-term sustainability.
- Debt Levels: AMGN's high debt levels raise concerns about its financial stability and ability to manage its debt burden.
- Growth Sustainability: The sustainability of AMGN's revenue growth without corresponding profit growth is a key concern.
-
Overall Assessment:
- AMGN is a large and established biotechnology company with strong revenue growth and cash flow generation. However, its lower profitability, efficiency, and high debt levels raise concerns about its financial health and long-term sustainability. Investors should carefully consider these factors before making an investment decision.